Jubilant Pharmova Ltd's Q3FY25 Quarter Results
- 01 Feb 2025
Result Summary
- Jubilant Pharmova Ltd reported a 3.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 6.9%.
- Its expenses for the quarter were up by 4.1% QoQ and 3.5% YoY.
- The net profit decreased 1.8% QoQ and increased 51.7% YoY.
- The earnings per share (EPS) of Jubilant Pharmova Ltd stood at 6.4 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1830.90 | 1774.00 | 1712.90 | 3.2% | 6.9% |
Total Expenses | 1681.20 | 1615.30 | 1625.00 | 4.1% | 3.5% |
Profit Before Tax | 130.80 | 144.50 | 87.90 | -9.5% | 48.8% |
Tax | 29.80 | 41.90 | 34.60 | -28.9% | -13.9% |
Profit After Tax | 100.70 | 102.50 | 66.40 | -1.8% | 51.7% |
Earnings Per Share | 6.40 | 6.50 | 4.20 | -1.5% | 52.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Jubilant Pharmova Ltd is a well-established player in the pharmaceutical industry. The company is primarily engaged in the manufacturing and distribution of pharmaceutical products, catering to a broad spectrum of health-related needs. Jubilant Pharmova's portfolio includes generic pharmaceuticals, specialty pharmaceuticals, and contract manufacturing services. As a key player in the industry, the company continually focuses on innovation and expansion to maintain its competitive edge. Recent developments in the pharmaceutical industry, such as advancements in drug delivery systems and increased demand for generics, are pertinent to the company's operations and market strategy. However, specific recent developments related to Jubilant Pharmova Ltd are not detailed in the provided information.
Revenue
For the third quarter of the fiscal year 2025 (Q3FY25), Jubilant Pharmova Ltd reported a total income of ₹1830.90 crores. This marks a 3.2% increase from the previous quarter (Q2FY25), where the total income was ₹1774.00 crores. Additionally, there is a year-over-year growth of 6.9% compared to the same quarter in the previous year (Q3FY24), where the total income was ₹1712.90 crores. The steady upward trend in revenue over both the quarter and the year may reflect the company's ongoing efforts to expand its market presence and diversify its product offerings. Such growth is critical for sustaining the company's operations and funding its strategic initiatives.
Profitability
In terms of profitability, Jubilant Pharmova Ltd recorded a Profit Before Tax (PBT) of ₹130.80 crores in Q3FY25. This figure represents a decline of 9.5% from the previous quarter's PBT of ₹144.50 crores. However, there is a significant year-over-year increase of 48.8% from Q3FY24, where the PBT was ₹87.90 crores. The Tax expense for Q3FY25 was ₹29.80 crores, showing a reduction of 28.9% from the previous quarter and a decrease of 13.9% from the same quarter last year. This led to a Profit After Tax (PAT) of ₹100.70 crores, which is 1.8% lower than the previous quarter's PAT of ₹102.50 crores but 51.7% higher than the PAT of ₹66.40 crores in Q3FY24. Earnings Per Share (EPS) for Q3FY25 is ₹6.40, slightly down by 1.5% from the previous quarter's EPS of ₹6.50, yet up by 52.4% from an EPS of ₹4.20 in Q3FY24.
Operating Metrics
Jubilant Pharmova Ltd's total expenses for Q3FY25 amounted to ₹1681.20 crores. This shows a 4.1% increase from the previous quarter's expenses of ₹1615.30 crores and a 3.5% rise from ₹1625.00 crores in Q3FY24. The increase in expenses over both the quarterly and yearly periods could be attributed to a variety of operational factors, including potential expansion activities, increased production costs, or strategic investments in research and development. The alignment of revenue growth with expense management is crucial for maintaining the overall financial health of the company. The financial data provided does not include specific ratios such as the P/E ratio, debt-to-equity ratio, or current ratio, which are essential for a deeper analysis of the company's financial stability and operational efficiency.
